HomeCompareTSBX vs JNJ

TSBX vs JNJ: Dividend Comparison 2026

TSBX yields 563.38% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TSBX wins by $156404.03M in total portfolio value
10 years
TSBX
TSBX
● Live price
563.38%
Share price
$0.36
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$156404.05M
Annual income
$115,926,179,183.70
Full TSBX calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — TSBX vs JNJ

📍 TSBX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTSBXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TSBX + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TSBX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TSBX
Annual income on $10K today (after 15% tax)
$47,887.32/yr
After 10yr DRIP, annual income (after tax)
$98,537,252,306.14/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, TSBX beats the other by $98,537,251,602.53/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TSBX + JNJ for your $10,000?

TSBX: 50%JNJ: 50%
100% JNJ50/50100% TSBX
Portfolio after 10yr
$78202.03M
Annual income
$57,963,090,005.74/yr
Blended yield
74.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

TSBX
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
Price Target
$0.50
+40.8% upside vs current
Range: $0.50 — $0.50
Altman Z
-23.2
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TSBX buys
0
JNJ buys
0
No recent congressional trades found for TSBX or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTSBXJNJ
Forward yield563.38%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$156404.05M$20.0K
Annual income after 10y$115,926,179,183.70$827.78
Total dividends collected$152979.84M$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$0.50$228.73

Year-by-year: TSBX vs JNJ ($10,000, DRIP)

YearTSBX PortfolioTSBX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$67,038$56,338.03$10,676$355.77+$56.4KTSBX
2$424,702$352,971.06$11,407$389.39+$413.3KTSBX
3$2,544,295$2,089,864.53$12,198$426.53+$2.53MTSBX
4$14,423,258$11,700,861.61$13,056$467.62+$14.41MTSBX
5$77,424,065$61,991,178.81$13,987$513.12+$77.41MTSBX
6$393,842,555$310,998,805.50$14,998$563.56+$393.83MTSBX
7$1,899,912,512$1,478,500,978.24$16,098$619.52+$1899.90MTSBX
8$8,698,653,014$6,665,746,626.53$17,295$681.69+$8698.64MTSBX
9$37,829,785,494$28,522,226,769.44$18,599$750.82+$37829.77MTSBX
10$156,404,049,663$115,926,179,183.70$20,022$827.78+$156404.03MTSBX

TSBX vs JNJ: Complete Analysis 2026

TSBXStock

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

Full TSBX Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this TSBX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TSBX vs SCHDTSBX vs JEPITSBX vs OTSBX vs KOTSBX vs MAINTSBX vs ABBVTSBX vs MRKTSBX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.